Short Interest
Shares sold short and not yet bought back, reported to FINRA twice a month by every member firm. This is a standing position, not daily trading — the two get confused constantly and mean very different things.
The number that frames everything else
4.3 days is the median time it would take to buy back the short position in a typical listed security at its own recent trading volume. Anything in low single digits is ordinary. The names at the top of this list would need weeks of their entire daily volume, which is the condition people are describing when they say a short is crowded.
| Ticker | Days to cover | Shares short | Change | Daily volume | Venue |
|---|---|---|---|---|---|
| IPSC Century Therapeutics, Inc. | 29.4M | -1.5% | 573,918 | SC | |
| FLWS 1-800-FLOWERS.COM, Inc. | 7.8M | -1.7% | 158,387 | NNM | |
| IMO Imperial Oil Limited | 20.1M | +0.7% | 440,359 | AMEX | |
| DMAC DiaMedica Therapeutics Inc. | 5.4M | +2.9% | 141,508 | SC | |
| IKT Inhibikase Therapeutics, Inc. | 19.7M | +2.8% | 553,489 | SC | |
| LCTX Lineage Cell Therapeutics, Inc. | 28.3M | -4.2% | 808,109 | AMEX | |
| EPRX Eupraxia Pharmaceuticals Inc. | 6.3M | +4.9% | 220,310 | SC | |
| NFE New Fortress Energy Inc. Class | 35.0M | -2.3% | 1.2M | NNM | |
| NTST NetSTREIT Corp. | 31.2M | -0.7% | 1.1M | NYSE | |
| RNA Atrium Therapeutics, Inc. | 3.5M | -1.0% | 126,745 | NNM | |
| SVRA Savara, Inc. | 38.5M | +4.6% | 1.4M | NNM | |
| AVIR Atea Pharmaceuticals, Inc. | 7.7M | +1.9% | 288,345 | NNM | |
| ANL Adlai Nortye Group Ltd. | 4.3M | +2.9% | 163,128 | NNM | |
| LUXE LuxExperience B.V. American Preferred | 3.9M | -0.3% | 153,810 | NYSE | |
| SPTX Seaport Therapeutics, Inc. Com | 3.0M | +9.2% | 119,904 | NNM | |
| IRON Disc Medicine, Inc. | 7.3M | -0.7% | 295,889 | NNM | |
| BBOT BridgeBio Oncology Therapeutic | 5.8M | -0.3% | 234,207 | NNM | |
| GTY Getty Realty Corporation | 8.2M | +5.2% | 337,768 | NYSE | |
| GPGI GPGI, Inc. Class A | 30.7M | -3.6% | 1.3M | NYSE | |
| OCGN Ocugen, Inc. | 101.8M | +0.9% | 4.3M | SC | |
| XRXDW Xerox Holdings Corporation War | 5.6M | +0.1% | 242,867 | NNM | |
| CRVS Corvus Pharmaceuticals, Inc. | 19.1M | +4.5% | 849,105 | NNM | |
| FDMT 4D Molecular Therapeutics, Inc. | 12.3M | +2.1% | 550,714 | NNM | |
| CIA Citizens, Inc. | 4.4M | +6.0% | 197,482 | NYSE | |
| PALI Palisade Bio, Inc. | 33.4M | -0.9% | 1.5M | SC | |
| WB Weibo Corporation | 16.1M | -2.2% | 732,042 | NNM | |
| SOBO South Bow Corporation | 11.3M | +7.7% | 516,557 | NYSE | |
| AVBP ArriVent BioPharma, Inc. | 8.2M | +2.3% | 378,015 | NNM | |
| PLCE Children's Place, Inc. (The) C | 3.4M | -1.8% | 157,518 | NNM | |
| RLAY Relay Therapeutics, Inc. | 41.4M | +2.8% | 1.9M | NNM | |
| GALT Galectin Therapeutics Inc. Com | 9.0M | +3.5% | 417,100 | SC | |
| ZBIO Zenas BioPharma, Inc. Common S | 11.7M | -0.8% | 553,670 | NNM | |
| HURA TuHURA Biosciences, Inc. | 6.3M | -2.8% | 301,575 | SC | |
| AIFC AI Financial Corporation Commo | 12.9M | +19.9% | 614,830 | SC | |
| TNGX Tango Therapeutics, Inc. | 43.2M | -3.2% | 2.1M | NNM | |
| BMEA Biomea Fusion, Inc. | 9.8M | -2.0% | 470,419 | NNM | |
| FTS Fortis Inc. | 15.7M | +23.1% | 771,308 | NYSE | |
| NBP NovaBridge Biosciences America | 4.6M | +1.3% | 225,162 | NNM | |
| AVTX Avalo Therapeutics, Inc. | 13.1M | +1.1% | 647,143 | SC | |
| KLRA Kailera Therapeutics, Inc. Com | 6.1M | -8.5% | 302,117 | NNM | |
| SRRK Scholar Rock Holding Corporation | 18.2M | +3.1% | 919,253 | NNM | |
| LXEO Lexeo Therapeutics, Inc. | 20.5M | +20.1% | 1.0M | NNM | |
| CHRS Coherus Oncology, Inc. | 24.0M | -2.2% | 1.2M | NNM | |
| NVX NOVONIX Limited American Depos | 4.0M | -2.1% | 204,815 | NNM | |
| SLDB Solid Biosciences Inc. | 16.6M | -2.4% | 847,638 | NNM | |
| PRTA Prothena Corporation plc | 8.5M | +4.6% | 436,939 | NNM | |
| IMRX Immuneering Corporation | 14.4M | -6.3% | 745,013 | NNM | |
| OZK Bank OZK | 15.8M | -7.3% | 815,309 | NNM | |
| CBUS Cibus, Inc. Class A Common Sto | 3.4M | -6.5% | 176,905 | SC | |
| DMRC Digimarc Corporation | 2.1M | -5.9% | 111,618 | NNM | |
| IMCR Immunocore Holdings plc | 7.9M | -3.9% | 420,023 | NNM | |
| TRON Tron Inc. Common Stock | 7.9M | +2.8% | 420,671 | SC | |
| XMAX XMAX, Inc. Common Stock | 10.6M | +13.5% | 563,616 | SC | |
| PROK ProKidney Corp. - Class A Ordinary Shares | 21.5M | +3.8% | 1.1M | SC | |
| ODTX Odyssey Therapeutics, Inc. Com | 2.2M | -1.0% | 120,560 | SC | |
| GIII G-III Apparel Group, LTD. | 7.6M | -3.4% | 408,083 | NNM | |
| FLNA Filana Therapeutics, Inc. Comm | 6.3M | -2.3% | 339,860 | SC | |
| CLM Cornerstone Strategic Investment Fund, Inc. | 34.5M | +10.1% | 1.9M | AMEX | |
| MESO Mesoblast Limited | 3.0M | -5.1% | 164,995 | NNM | |
| CATX Perspective Therapeutics, Inc. | 23.0M | -1.9% | 1.3M | AMEX | |
| NRIX Nurix Therapeutics, Inc. | 18.0M | -2.0% | 993,103 | NNM | |
| SANA Sana Biotechnology, Inc. | 42.6M | +1.0% | 2.4M | NNM | |
| CASH Pathward Financial, Inc. | 2.2M | +0.5% | 123,486 | NNM | |
| RNAC Cartesian Therapeutics, Inc. | 1.9M | +1.3% | 104,625 | NNM | |
| CD Chaince Digital Holdings Inc. | 5.0M | +4.2% | 283,339 | NNM | |
| KOD Kodiak Sciences Inc | 10.3M | +0.7% | 589,066 | NNM | |
| TSHA Taysha Gene Therapies, Inc. | 46.7M | +0.1% | 2.7M | NNM | |
| LFCR Lifecore Biomedical, Inc. Comm | 2.4M | -7.3% | 139,166 | NNM | |
| CM Canadian Imperial Bank of Commerce | 14.4M | -1.5% | 833,302 | NYSE | |
| OTTR Otter Tail Corporation | 4.9M | -4.1% | 282,346 | NNM | |
| CBIO Crescent Biopharma, Inc. | 3.2M | -7.2% | 187,795 | SC | |
| CV CapsoVision, Inc. Common Stock | 1.8M | -6.7% | 104,306 | SC | |
| CURV Torrid Holdings Inc. | 4.1M | +3.1% | 240,232 | NYSE | |
| CURB Curbline Properties Corp. | 19.0M | +3.8% | 1.1M | NYSE | |
| QNC Quantum eMotion Corp. | 7.1M | -0.8% | 420,852 | AMEX | |
| SKIN SkinHealth Systems Inc. Class | 7.1M | -6.9% | 419,851 | SC | |
| NGNE Neurogene Inc. | 3.0M | +1.1% | 180,803 | NNM | |
| VUZI Vuzix Corporation | 16.0M | +1.3% | 965,424 | SC | |
| IDYA IDEAYA Biosciences, Inc. | 10.4M | +2.8% | 629,939 | NNM | |
| PTGX Protagonist Therapeutics, Inc. | 7.8M | +3.3% | 474,581 | NNM | |
| EH EHang Holdings Limited - ADS | 8.3M | -6.3% | 511,836 | NNM | |
| MAZE Maze Therapeutics, Inc. Common | 6.0M | +5.5% | 370,295 | NNM | |
| PROF Profound Medical Corp. Common | 1.8M | +2.0% | 114,102 | SC | |
| TEAD Teads Holding Co. Common Stock | 3.1M | -2.0% | 194,005 | NNM | |
| EPRT Essential Properties Realty Trust, Inc. | 18.9M | +5.3% | 1.2M | NYSE | |
| BEAM Beam Therapeutics Inc. | 24.4M | +3.7% | 1.5M | NNM | |
| UPXI Upexi, Inc. | 15.1M | -2.8% | 939,703 | SC | |
| FLNG FLEX LNG Ltd. Ordinary Shares | 4.8M | +7.4% | 297,386 | NYSE | |
| HPK HighPeak Energy, Inc. | 9.3M | +19.3% | 581,808 | NNM | |
| SYRE Spyre Therapeutics, Inc. | 11.8M | -3.2% | 736,817 | NNM | |
| CTMX CytomX Therapeutics, Inc. | 34.6M | -1.4% | 2.2M | NNM | |
| XRX Xerox Holdings Corporation | 39.2M | +3.5% | 2.5M | NNM | |
| PCVX Vaxcyte, Inc. | 14.8M | +2.3% | 933,368 | NNM | |
| SLP Simulations Plus, Inc. | 2.8M | -0.9% | 178,271 | NNM | |
| CAR Avis Budget Group, Inc. | 5.4M | -1.7% | 344,731 | NNM | |
| TR Tootsie Roll Industries, Inc. | 2.2M | -7.2% | 138,778 | NYSE | |
| PBLS Parabilis Medicines, Inc. Comm | 5.3M | +2.7% | 334,084 | NNM | |
| RCI Rogers Communication, Inc. | 17.0M | +23.2% | 1.1M | NYSE | |
| BF.B Brown Forman Inc Class B | 26.0M | -8.2% | 1.7M | NYSE | |
| CHPT ChargePoint Holdings, Inc. | 5.8M | +10.2% | 368,731 | NYSE |
Showing 100 exchange-listed securities with at least 1 million shares short and 100 thousand shares of average daily volume. 12,959 exchange-listed securities reported a position on this settlement date, totalling 44.1 billion shares. OTC issues are reported too and are excluded here.
What days to cover actually measures
Days to cover is the short position divided by the security's average daily trading volume. It answers one question: if every short seller decided to buy back at once, and they were the only buyers, how many full trading days would that take?
That framing is the whole point. A position of ten million shares means nothing by itself — it is enormous in a security that trades two hundred thousand shares a day and trivial in one that trades forty million. The ratio is what makes two securities comparable.
It is also the mechanism behind a squeeze, which is why the metric gets attention. When the number is large, the shorts cannot exit without being the dominant buyer for days on end, and their own buying pushes the price against them. When it is one or two, they can be out by lunchtime and nothing is crowded about the position.
Three measurements, one word
“Short” gets used for three datasets that do not measure the same thing, and reading one as another produces confident nonsense.
- Short interest — this page. A balance: shares borrowed, sold, and not yet bought back, as of a settlement date. Reported twice a month.
- Short volume — a flow. Trades flagged short on the day they execute. Most of it is a market maker shorting to fill your buy order and flattening minutes later, which is why the market-wide median sits near half and means nothing.
- Fails to deliver — a settlement break. Shares that did not arrive on time. Overwhelmingly operational, and explicitly not evidence of naked shorting.
A security can be high on one and low on the others. Reading them together is the only way any of them is informative.
Why this page does not show percent of float
Percent of float is the number most sites lead with, and it is the number we cannot honestly print. Float — shares actually available to trade, after insiders and restricted holdings — is not in any filing. Every float figure in circulation is a commercial vendor's estimate, they disagree with each other by material amounts, and they are licensed. Publishing one here would mean republishing a vendor's proprietary estimate as though it were the regulatory filing it sits next to.
Days to cover uses FINRA's own average-volume figure from the same file, so every number on this page comes from the one source.
Limits worth stating
- It lags. Positions are as of a settlement date roughly a week before publication, and the file arrives twice a month. In a fast-moving name the real position has already changed.
- Volume is FINRA's, not the consolidated tape. For a security whose trading is mostly on a foreign primary listing, the US average volume understates reality and days to cover comes out far too high. Several perennial members of this list are exactly that case rather than crowded shorts.
- A position is not a view. A large short can be one leg of a convertible-arbitrage or merger-arbitrage trade, or an index hedge, with no directional opinion attached at all.
- Zero-volume securities are dropped. FINRA writes a sentinel value where average volume is zero; it is stored as no value rather than as an enormous days-to-cover figure.
Where this comes from
FINRA publishes a consolidated short interest file twice a month, free and public, covering every equity security its members report. It is parsed here directly. Each security's own page pulls this together with its filings, ownership and settlement fails — see any ticker under security pages, or the rest of the Markets section.